Epigenetic induction of CD1d expression primes lung cancer cells for killing by invariant natural killer T cells

Éilis Dockry\textsuperscript{a,b}, Seónadh O’Leary\textsuperscript{c}, Laura E. Gleeson\textsuperscript{c,d}, Judith Lyons\textsuperscript{d}, Joseph Keane\textsuperscript{c,d}, Steven G. Gray \textsuperscript{b,\textdagger}, and Derek G. Doherty \textsuperscript{\textdagger}\textsuperscript{b,\textdagger}

\textsuperscript{a}Department of Immunology, Trinity Translational Medicine Institute, Trinity College Dublin, Dublin, Ireland; \textsuperscript{b}Thoracic Oncology Research Group, Trinity Translational Medicine Institute, Trinity College Dublin, Dublin, Ireland; \textsuperscript{c}Department of Clinical Medicine, Trinity Translational Medicine Institute, Trinity College Dublin, Dublin, Ireland; \textsuperscript{d}Department of Respiratory Medicine, St. James’ Hospital, Dublin, Ireland

ABSTRACT
Immunotherapies that target CD1d-restricted invariant NKT (iNKT) cells can prevent tumor growth in murine models but trials in humans have shown limited clinical efficacy. Here, we show that iNKT cells are depleted from blood and bronchial lavage samples from patients with non-small cell lung cancer (NSCLC) suggesting a role for these cells in immunity against NSCLC. We interrogated the Lung Cancer Explorer and Kaplan-Meier Plotter databases of NSCLC patients and found that pulmonary CD1d expression is reduced in patients with NSCLC and that low expression of CD1d mRNA is significantly associated with poor patient survival. We hypothesized that CD1d expression in NSCLC is epigenetically regulated and can be modulated using epigenetic targeting therapies. Treatment of the CD1d-negative NSCLC cell lines, A549 and SK-MES-1, with DNA methylation inhibitors and histone deacetylase inhibitors resulted in a dose-dependent induction of CD1d mRNA and protein expression. Chromatin immunoprecipitation analysis indicated that this induction of CD1d expression directly involved chromatin remodelling. Induction of CD1d expression by A549 and SK-MES-1 cells using therapeutic low doses of DNA methyltransferase inhibitors and histone deacetylase inhibitors made them targets for iNKT cell-mediated cytolytic degranulation. Thus, epigenetic manipulation of CD1d expression may augment the efficacy of iNKT cell-based immunotherapies for NSCLC.

Introduction
Lung cancer is the most common cause of cancer-related death worldwide, accounting for about 13% of all cancer diagnoses and 19% of cancer mortalities.\textsuperscript{1} Non-small cell lung cancer (NSCLC) accounts for approximately 85% of all lung cancer cases and can be classified into adenocarcinoma, squamous cell carcinoma, and large cell carcinoma. Mortality rates in NSCLC remain high because of difficulties in detection and resistance to current therapeutics. Surgical resection is a treatment for localized NSCLC, but only 15–40% of patients are considered candidates for surgery at diagnosis.\textsuperscript{2} Platinum-based therapy is the current gold standard of care for NSCLC patients,\textsuperscript{3} however, survival is only marginally improved in advanced NSCLC. The median survival for a patient with advanced NSCLC is approximately 1 year and only 3.5% of patients with advanced disease survive five years following diagnosis. In addition, many tumors develop resistance to current chemotherapies. Therefore, there is an urgent need to develop novel therapeutics for NSCLC.

We postulated that cellular therapies involving invariant natural killer T (iNKT) cells could benefit patients with NSCLC. iNKT cells are cytotoxic T lymphocytes that express NK cell markers and a TCR composed of an invariant \(\alpha\)-chain (\(\alpha\text{24}\beta\text{18}\) in humans and \(\alpha\text{24}\beta\text{18}\) in mice) paired with one of a limited number of \(\beta\)-chains.\textsuperscript{4,5} iNKT cells recognise glycolipid antigens presented by the MHC class I-like molecule CD1d. They can recognise a number of self and bacterial glycolipids, however, most studies on murine and human iNKT cells have used the xenogenic glycolipid \(\alpha\)-galactosylceramide (\(\alpha\text{-GalCer}\)).\textsuperscript{6} Upon activation by \(\alpha\text{-GalCer}\), iNKT cells can kill a wide range of tumor cell lines\textsuperscript{7,8} and rapidly secrete a diverse range of growth factors and cytokines that activate and polarize adaptive immune responses.\textsuperscript{9-11} Activated iNKT cells can also interact directly with other cells of the immune system, and can induce the maturation of DC into APC\textsuperscript{12,13} and of B cells into antibody secreting plasma cells.\textsuperscript{14,15} Therapeutic activation of iNKT cells in murine models can prevent and reverse tumor growth.\textsuperscript{7,16,17} Numerical and functional iNKT deficiencies have been reported in a number of human cancers including NSCLC.\textsuperscript{18-21} but clinical trials that have targeted iNKT cells in humans have to date shown limited efficacy.\textsuperscript{22-24} In the present study, we show that iNKT cells are depleted from the blood and lungs of NSCLC patients. We also interrogated the Lung Cancer Explorer and Kaplan-Meier Plotter (KMPlot) databases...
of patients with NSCLC and found that CD1d expression is lower in the lungs of patients with NSCLC compared to healthy lungs, and that low expression of CD1d mRNA is significantly associated with poor patient survival. We hypothesized that NSCLC cells may downregulate CD1d expression to evade recognition by iNKT cells.

Epigenetic alterations such as aberrant DNA methylation and histone acetylation are widespread in NSCLC. Hypermethylation of the promoter sequences of a number of tumor suppressor genes, resulting in loss of expression, occurs in most cases of NSCLC and is associated with tumor recurrence and shorter survival times following resection. DNA methyltransferases (DNMT) are overexpressed in NSCLC, leading to hypermethylation of tumor suppressor genes. Conversely, histone deacetylases (HDAC), which remove acetyl groups from ε-N-acetyl lysine amino acids on histones resulting in gene activation, are aberrantly expressed in NSCLC, which is associated with poor prognosis in NSCLC.

Epigenetic modifications also play key roles in downregulating expression of molecules that are critical for immunogenicity and tumor recognition, leading to tumour evasion. Aberrant hypermethylation of MHC genes resulting in downregulated MHC class I protein expression has been demonstrated in gastric carcinoma and oesophageal squamous cell carcinoma. Treatment of oesophageal squamous cell and gastric carcinoma cell lines with decitabine (5-aza-2'-deoxycytidine or DAC), an inhibitor of DNA methylation, restored MHC class I expression. DNMT and HDAC inhibitors can also prevent the suppression of NKG2D ligand expression by tumor cells resulting in increased NKG2D-mediated activation of cytotoxic T cells and NK cells.

A study by Yang and colleagues found that CD1d expression could be induced in lung adenocarcinoma cell lines from both mice and humans using HDAC inhibitors. This study showed that CD1d expression could be induced, either through knockdown of HDAC genes, or treatment with HDAC inhibitors trichostatin A (TSA) or suberoylanilide hydroxamic acid (SAHA). The reversible nature of epigenetic modifications makes them an attractive prospect as novel therapeutic targets for cancer. DNMT inhibitors such as DAC and HDAC inhibitors such as SAHA have been approved for the treatment of some cancers. In the present study we have investigated if DAC, TSA and SAHA can induce CD1d expression on NSCLC adenocarcinoma (A549) and squamous cell carcinoma (SKMES-1) cell lines. We show that all epigenetic modulators tested induced CD1d mRNA and protein expression by both cell lines and that treatment with DAC sensitized NSCLC cells for killing by iNKT cells. Thus, epigenetic regulation of CD1d expression may benefit NSCLC patients by helping to overcome immune evasion by tumor cells.

**Results**

**iNKT cells are depleted from the blood and lungs of patients with NSCLC**

PBMCs were prepared from blood samples of 9 NSCLC patients and 13 healthy donors, and stained with mAbs specific for CD3 and Vα24/pra18, and analysed by flow cytometry (Fig. 1A). iNKT cell frequencies were determined as percentages of lymphocytes that expressed CD3 and Vα24/pra18. Absolute numbers of iNKT cells per millilitre of blood or BAL were calculated. Fig. 1B shows that the frequencies and absolute counts of circulating iNKT cells were significantly decreased in NSCLC patients compared to healthy controls.

The frequencies and numbers of iNKT cells in bronchoalveolar lavage (BAL) samples from 7 NSCLC patients and 26 non-cancer controls were determined after removal of macrophages by adherence purification. Cells were washed with PBS and stained with mAbs specific for CD3 and Vα24/pra18, and analysed by flow cytometry. Fig. 1C shows that iNKT cells were undetectable in BAL samples from NSCLC patients, but accounted for up to 0.15% of lymphocytes in BAL from non-cancer control subjects. These results show that iNKT cells are depleted from the blood and lungs of patients with lung cancer.

**CD1d expression in lung tissue is reduced in patients with NSCLC**

CD1d expression levels were compared between datasets on 498 samples of lung adenocarcinoma, 492 samples of lung squamous cell carcinoma and 59 samples of healthy lung by interrogating the Lung Cancer Explorer database. The relative levels of CD1d expression were significantly lower in the patients with adenocarcinoma (P = 3.3 × 10⁻⁵) and squamous cell carcinoma (P = 1.3 × 10⁻¹⁵) compared to controls (Fig. 2). A study by Yang and colleagues found that CD1d expression could be induced in lung adenocarcinoma cell lines from both mice and humans using HDAC inhibitors. This study showed that CD1d expression could be induced, either through knockdown of HDAC genes, or treatment with HDAC inhibitors trichostatin A (TSA) or suberoylanilide hydroxamic acid (SAHA). The reversible nature of epigenetic modifications makes them an attractive prospect as novel therapeutic targets for cancer. DNMT inhibitors such as DAC and HDAC inhibitors such as SAHA have been approved for the treatment of some cancers. In the present study we have investigated if DAC, TSA and SAHA can induce CD1d expression on NSCLC adenocarcinoma (A549) and squamous cell carcinoma (SKMES-1) cell lines. We show that all epigenetic modulators tested induced CD1d mRNA and protein expression by both cell lines and that treatment with DAC sensitized NSCLC cells for killing by iNKT cells. Thus, epigenetic regulation of CD1d expression may benefit NSCLC patients by helping to overcome immune evasion by tumor cells.

**High expression of CD1d in NSCLC is associated with significantly improved overall survival**

CD1d mRNA expression in tumors from NSCLC patients was analysed using the KMPlot database. Univariate analysis of mRNA expression in 1,926 NSCLC patients of all histologies determined that overall survival was significantly improved in NSCLC patients with high levels of CD1d mRNA expression (CD1d-high) compared with those who had low levels of CD1d mRNA expression (CD1d-low) (P = 0.0013), with a median overall survival of 56.8 months versus 76 months (Fig. 3A). Multivariate analysis confirmed that this benefit in overall survival based on CD1d-high and CD1d-low NSCLC patients was present regardless of grade, staging, treatment, gender or smoking status (P = 0.0014). When separated according to histological subtype, univariate analysis of survival for CD1d mRNA expression in 720 lung adenocarcinoma patients (Fig. 3B) and 524 lung squamous cell carcinoma patients (Fig. 3C), found that there was no significant difference in overall survival between CD1d-high and CD1d-low lung adenocarcinoma patients, however high CD1d expression in lung squamous cell carcinoma was associated with improved overall survival (P = 0.031; Fig. 3C).

To determine whether gender or smoking status can affect overall survival in NSCLC patients, CD1d mRNA expression was assessed in the same dataset based on sex, smoking status, or in never smokers (Fig. 4). Using univariate analysis we found that high CD1d mRNA expression is associated with significantly improved overall survival.
associated with improved survival in males ($P = 0.0057$; Fig. 4A) and smokers ($P = 0.037$; Fig. 4C). There was no significant difference in overall survival between CD1d-high and CD1d-low females (Fig. 4B) and never smokers (Fig. 4D). These results show that low CD1d expression is associated with poorer survival rates in NSCLC.

We also compared survival rates of NSCLC patients with low and high levels of expression of a set of key inflammation-related genes identified by Loza and co-workers,$^{45}$ using the KM Plot database. High expression of 8 out of 12 genes tested (IL-4R, CTLA4, PTPN22, IRF5, NOD2, TGFβ, MDA5 and CASP8) was significantly associated with improved survival (data not shown). Interrogation of the Lung Cancer Explorer database, revealed that the expression levels of all of these genes correlate positively with CD1d expression levels (not shown). Therefore, the high CD1d
expression observed is associated with a generalized immune activation in the lungs.

**Histone acetylation and DNA methylation inhibitors induce expression of CD1d mRNA in A549 and SK-MES-1 cells**

The human adenocarcinoma alveolar basal epithelial cell line, A549, and the human lung squamous cell carcinoma cell line, SK-MES-1, were treated with HDAC inhibitor TSA at 250 ng/ml or vehicle control for a period of 24 h. Following treatment, RNA was extracted and quantified and CD1d mRNA expression was examined by RT-PCR (Fig. 5A). Changes in CD1d expression were expressed as ratios of CD1d to β-actin mRNA. Fig. 5B shows that a significant upregulation of CD1d was observed in A549 cells in response to TSA treatment (P = 0.0002). A similar upregulation of CD1d expression by SK-MES-1 cells was also observed (Fig. 5C; P = 0.0026).

A549 and SK-MES-1 cells were also treated with the HDAC inhibitor SAHA at 5 μM or vehicle control for a period of 24 h. In order to determine whether the effects of this treatment could be maintained over time, the cells were treated with SAHA as before and then washed with PBS to remove SAHA and left for 24 hours. RNA was extracted and CD1d mRNA was quantified by RT-PCR. A significant up-regulation of CD1d was observed in A549 cells (P < 0.0001; Fig. 5D) and SK-MES-1 cells (P = 0.0002; Fig. 5E) in response to SAHA treatment. This increase in CD1d expression was maintained in A549 cells but not SK-MES-1 cells after a 24 h recovery period (P = 0.0012).

We also investigated the effects of treating A549 cells with DAC and GEM on CD1d mRNA expression. We have previously shown that GEM, a chemotherapeutic agent, can function as a DNMT inhibitor with equivalent activity to DAC.46 A549 cells were treated with 200 nM and 1 μM DAC or GEM for 48 hours. For both treatments, the media and drugs were replaced at 24 hours. Following the treatment period CD1d mRNA was examined by RT-PCR. Fig. 5F shows that CD1d expression was significantly increased in A549 cells treated with DAC at 1 μM (P = 0.037), GEM at 200 nM (P = 0.0019) and GEM at 1 μM (p < 0.0001). These results show that...
treatment with HDAC and DNMT inhibitors can induce CD1d expression in NSCLC cell lines at the mRNA level.

Chromatin immunoprecipitation (ChIP) analysis of the CD1d promoter from A549 cells treated with TSA verified that the observed effects for HDAC inhibitors were due to increased histone hyperacetylation. Fig. 6 shows that treatment with TSA resulted in an increase in PCR product, showing enhanced histone hyperacetylation at the CD1d promoter. Histone acetylation is associated with gene expression, indicating that the CD1d promoter region was silenced in A549 cells due to aberrant histone deacetylation. Treatment with TSA prevented gene silencing by HDACs allowing for the gene to be expressed. Both lysine 9 and 14 were hyperacetylated following treatment. These are known activating marks of expression.47 In addition, a decrease in expression was observed at the histone H3 lysine 4 monomethylation repressive mark with a simultaneous increase in levels of an activating mark, H3K4me2. Methylation marks are also associated with gene silencing; a decrease in the expression of a known repressive methylation mark, H3K9me2, further indicates that gene expression has been induced. The ChIP analysis confirms that chromatin remodelling is directly involved in with the induction of CD1d gene expression.

Transient low-dose DAC induces CD1d protein expression by A549 cells and SK-MES-1 cells

Past trials with high doses of DAC have been plagued by extreme toxicities.48 Transient low doses of DAC have been shown to sustain long-term anti-tumor effects and are at least temporally associated with their ability to maintain their targeting of DNMTs and alterations of gene expression.49 A549 (Fig. 7A) and SK-MES-1 cells (Fig. 7B and supplemental Fig. 1) were treated with PBS or DAC at either 50 nM, 100 nM or 1 μM over 72 hours. Media and DAC were replaced every 24 hours. Cells were assessed for expression of CD1d by flow cytometry immediately following treatment and at four days post-treatment. Fig. 7C shows a significant induction of CD1d protein expression in A549 cells at 4 days post treatment. A significant induction of CD1d protein expression in SK-MES-1 cells was observed immediately following treatment and at day 4 post treatment. In addition, the increased CD1d expression due to treatment with 1 μM DAC remained significant after 4 days of recovery (Fig. 7D). These results show that transient low dose DAC treatment is
accompanied by a prolonged induction of CD1d protein expression in NSCLC cell lines.

**iNKT cells degranulate in response to low dose DAC-treated A549 cells**

To investigate if low dose DAC treatment can increase susceptibility of A549 cells to cytotoxicity by iNKT cells, A549 cells were treated with PBS or DAC at 50 nM, 100 nM and 1 μM for 72 h. The media and treatments were replaced every 24 h. Cells were then pulsed with 100 ng/ml of the glycolipids α-GalCer or 7DW8-5 or vehicle alone for 24 hours before adding iNKT cells. All iNKT cell lines used contained >98% CD3+ Vα24Jα18 TCR+ cells (Fig. 8A) and included CD4+, CD8+ and double negative CD4−CD8− subpopulations as assessed by flow cytometry (Fig. 8B). Treated and pulsed A549 cells were co-cultured with iNKT cells and a mAb specific for CD107a for 4 hours. Cell-surface CD107a expression by the iNKT cells was examined by flow cytometry (Fig. 8C). Fig. 8D shows that iNKT cells co-cultured with A549 cells treated with 50 nM − 1 μM DAC showed dose-dependent induction of CD107a when pulsed with α-GalCer (P < 0.01 – p < 0.001) or 7DW8-5 (p < 0.05 – p < 0.001). Little or no degranulation occurred in the absence of CD1d-binding glycolipids but significant degranulation occurred when DAC-untreated A549 cells were pulsed with the glycolipids. These results show that iNKT cells can kill A549 cells and that low dose DAC treatment increases their susceptibility to iNKT cell cytotoxicity. This cytolytic
degranulation was reduced by up to 50% using a blocking antibody specific for CD1d (Fig. 8E), confirming at least a partial requirement for CD1d in iNKT cell mediated cytotoxicity.

**iNKT cells degranulate in response to low dose DAC-treated SK-MES-1 cells**

To assess whether lower, less toxic concentrations of DAC can increase susceptibility of SK-MES-1 cells to cytotoxicity by iNKT cells, SK-MES-1 cells were treated with MeOH, PBS or DAC at either 50 nM, 100 nM or 1 μM for 72 h. Both media and treatments were replaced every 24 h. MeOH was used as a vehicle control. After 72 h cells were stained with an anti-CD1d mAb and analysed by flow cytometry. A and B, Flow cytometric dot plots showing CD1d expression by A549 cells (A) and SK-MES-1 cells (B), showing a fluorescence-minus-one (FMO) dot plots of DAC-treated cells (left panels), vehicle (MeOH)-treated cells (centre) and DAC-treated cells (right). C, Mean (± SEM) frequencies of A549 cells that expressed CD1d 4 days after cessation of treatment. D, Mean (± SEM) frequencies of SK-MES-1 cells that expressed CD1d immediately following cessation of treatment and 4 days after cessation of treatment. A two-way ANOVA with Bonferroni’s post hoc test was used to determine significance. Results are representative of 3 experiments.

**Discussion**

CD1d-restricted iNKT cells promote anti-tumor immunity in humans and animals, but iNKT cells from cancer patients are frequently depleted and/or functionally-impaired. We enumerated iNKT cells in BAL and peripheral blood samples from NSCLC patients and compared them to those of control subjects. We found that iNKT cells were significantly depleted from both tissues in the NSCLC patients. This led us to
hypothesize that iNKT cells represent an important component of anti-tumor immunity against NSCLC and that immunotherapies that boost their numbers and activities may benefit patients.

Whereas the therapeutic capacity of iNKT cells for cancer is well-documented in murine models, several phase I trials in humans using α-GalCer, α-GalCer-loaded DC, or ex vivo-expanded autologous iNKT cells in humans have shown little therapeutic benefit. α-GalCer caused minimal toxicity in humans but only a small subset of patients achieved disease stabilisation or partial response. The discrepancies between mouse and human trials may be the result of dramatic differences in iNKT abundancies and subset distributions between the two species, or to factors related to tumor stage and ongoing therapies. The low clinical efficacies of the iNKT cell-based immunotherapies tested in humans to date may also be due to the fact that tumor cells frequently do not express CD1d. Some tumor types such as prostate cancers, myelomonocytic leukæmia and some neurologic tumours, express CD1d and as such can be targeted for NKT-mediated cell killing. However, most human and mouse solid tumors are CD1d-negative. Over the last number of years increasing evidence has suggested that cancer cells are capable of downregulating MHC class I molecules in an attempt to evade immunosurveillance. Downregulation of CD1d has been documented in many tumor types including breast and cervical carcinoma and is associated with increased malignancy. We hypothesized that NSCLC cells similarly downregulate CD1d expression to evade the actions of iNKT cells. Such downregulation of CD1d expression could be the result of epigenetic modifications that take place in cancer cells.

To determine whether CD1d expression is altered in patients with NSCLC, we interrogated the Lung Cancer Explorer database and found that CD1d expression is significantly lower in the lungs of patients with lung adenocarcinoma and squamous cell carcinoma. Furthermore, by interrogating the KMPlot database, we found that low expression of CD1d was associated with significantly worse overall survival in patients with NSCLC. We then analysed NSCLC patients for variations in overall survival due to NSCLC histology, gender and smoking status. Using univariate analysis we found that high expression of CD1d was associated with significantly improved overall survival in squamous cell carcinoma patients, males and smokers. 48% of the adenocarcinoma patients and 71% of the squamous cell carcinoma patients were male, therefore the over-representation of males in the squamous cell carcinoma group, may contribute to the significance of the link between high CD1d expression and survival in this group. While low CD1d expression is associated with poor overall survival in NSCLC patients, we found that low levels of expression of a number of other markers of immune activation were also found to be associated with worse patient survival. This could either reflect a direct influence of CD1d on survival or could just be a marker for immune activation in the tumor.
Epigenetics is defined as the sum of all stable and heritable changes to gene expression that do not occur as a result of changes to the underlying DNA sequence. Chromatin structure defines the condition in which DNA is organised and allows for transcriptional repression or activation of genes. Epigenetic mechanisms such as DNA CpG methylation and histone post-translational modifications affect chromatin structure and gene expression by changing the accessibility of transcription factors to the promoter regions of genes. Aberrant acetylation patterns also contribute to cancer proliferation in various cancers, including gastric and lung, and over-expression of HDACs have been observed in lung cancer.

Treatment with HDACi TSA and SAHA were shown to induce CD1d expression in A549 cells. We hypothesized that CD1d expression is epigenetically regulated and that treatment with DNMTi and HDACi could induce CD1d expression in NSCLC cancer cell lines. A549 and SK-MES-1 cells were treated with HDACi TSA and SAHA, and CD1d was found to be significantly increased at the mRNA level and this significant increase in expression was maintained following a recovery period in SAHA-treated A549 cell lines. HDAC inhibitors prevent the action of HDACs which silence genes by removing acetyl groups from histones. These results corroborate evidence that HDACs are over-expressed in lung cancer. To see whether a similar induction of CD1d expression was possible using DNMTi, A549 and SK-MES-1 cells were treated with DAC and GEM. Both cell lines showed an increase in CD1d expression at the mRNA following DNMTi treatment indicating that aberrant DNA methylation patterns affect the expression of CD1d in NSCLC. Treatment with DNMT inhibitors remove hypermethylation of the CD1d promoter resulting in an upregulation of CD1d expression. To assess whether the changes in CD1d expression were due to direct conformational changes at the promoter region, a ChIP analysis was performed on A549 cells treated with TSA. The analysis showed that HDAC inhibition causes a conformational change in the chromatin landscape, allowing histone post-translational modifications to occur at the promoter region of the CD1d gene.

We hypothesized that DAC could be used to induce CD1d expression at the protein level in A549 and SK-MES-1 cell lines, and that this induction would correlate with increased iNKT cell-mediated cytolytic degranulation. High dose DAC treatment is associated with extreme toxicities whereas transient DAC treatment have been shown to sustain long-term anti-tumor effects and to maintain its
targeting of DNA methylation processes and alterations of gene expression. A549 and SK-MES-1 treated with a series of low dose DAC treatments were found to induce and maintain CD1d expression for up to four days. This increase in CD1d expression was associated with an increase in cytolytic degranulation by iNKT cells when the tumor cells were pulsed with the iNKT cell agonist ligands α-GalCer or 7DW8-5. No degranulation occurred in the absence of α-GalCer or 7DW8-5 but significant degranulation occurred when iNKT cells were co-cultured with DAC-untreated A549 and SK-MES-1 cells treated with these glycolipids. This suggests that the untreated tumor cell lines express low levels of CD1d and these levels are augmented by treatment with DAC. Antibody blocking of CD1d indicated that cytolytic degranulation by iNKT cells in response to DAC-untreated or DAC-treated A549 and SK-MES-1 cells is at least partially CD1d-dependent. While it is possible that stimulatory ligands other than CD1d, such as MHC or ligands for NKG2D, may contribute to iNKT cell cytotoxicity, this is unlikely because iNKT cell degranulation only occurred in the presence of the CD1d-binding glycolipids α-GalCer or 7DW8-5.

This study has shown that it is possible to increase CD1d expression in NSCLC cell lines using epigenetic targeted therapies in vitro and that this increase in expression is associated with increased cytolytic degranulation by iNKT cells. This observation is noted for both an adenocarcinoma and a squamous cell carcinoma cell line, but future studies are required to determine if the same treatment can induce CD1d expression by fresh tumor cells. Our results suggest that epigenetic modifying agents may augment the efficacies of iNKT cell based immunotherapies, which in turn may complement current chemotherapies for NSCLC. The epigenetic agents used in this study are FDA approved drugs that are indicated in the treatment of acute myeloid leukemia and cutaneous T cell lymphoma. By combining iNKT-based therapeutic strategies with epigenetic targeting agents, both of which have previously been found to have therapeutic benefit in other patient populations, personalized medicines may be devised to combat the high mortality rates and poor treatment options associated with NSCLC.

Materials and methods

Subjects

Venous blood samples were obtained from 9 chemotherapy-naive patients with NSCLC (5 females and 4 males; median age 60; range 53–75) and 13 healthy donors (8 females and 5 males; median age 59; range 50–64) after informed consent. BAL samples were obtained from 33 patients over 18 years of age who were undergoing a clinically-indicated bronchoscopy and had given written informed consent for retrieving additional bronchial washings for research. Of these, 7 patients had confirmed NSCLC (1 female and 5 males; median age 67.5; age range 57–81) and 26 were non-cancer subjects (15 females and 12 males; median age 62; age range 32–91) and did not have a known (or ensuing) diagnosis of malignancy or sarcoidosis. Ethical approval for this study was obtained from the Research Ethics Committee of St. James’s Hospital, Dublin.

Blood and BAL preparation

PBMC were prepared from blood samples by standard density gradient centrifugation over Lymphoprep™ (Axis-Shield). BAL samples were obtained during bronchoscopy. 150 ml of saline was injected into the lungs and 50–90 ml was retrieved. Samples were plated overnight to remove macrophages by adherence purification, as previously reported. Cells were washed thrice with PBS and counted before analysis by flow cytometry.

Antibodies and flow cytometry

A mAb specific for CD1d was obtained from BD Biosciences (555749). MAb specific for CD3 (300330), CD4 (344612), CD8α (300908), CD107a (328605) and the Vα24Jα18 TCR found on iNKT cells (clone 6B11; 342908) were obtained from BioLegend. Cells were stained with mAbs in PBS containing 1% bovine serum albumin and 0.02% sodium azide, and analysed using a FACSCanto II flow cytometer (BD Biosciences) and FlowJo software (Tree Star). Lymphocytes were gated on and any doublets or dead cells were excluded from the analysis. Single stained controls were used to set compensation parameters and fluorescence-minus-one controls were used to set gates. iNKT cell frequencies were expressed as percentages of lymphocytes. Absolute numbers of iNKT cells were determined from viable cell counts and expressed as cells/ml of blood or BAL.

Analysis of associations between CD1d mRNA expression and incidence and survival of NSCLC

CD1d expression levels were compared between lung adenocarcinoma, squamous cell carcinoma and healthy lung by interrogating the Lung Cancer Explorer database (https://qbrc.swmed.edu/projects/lungcancer/), which used datasets obtained by molecular profiling of patients and control subjects enrolled in the Cancer Genome Atlas Research Network. NSCLC patient groups in the KMPlot database were analysed to determine whether high CD1d mRNA expression is associated with improved overall survival. Patients were divided into high and low CD1d mRNA expression groups, with the best performing threshold being used as the final cut-off in a univariate Cox regression analysis. Basic univariate analysis was performed to assess overall survival in NSCLC patients of all histologies. Additional univariate analyses were performed to see whether overall survival rates differed between histological subtypes, genders and smoking status. The analysis was considered significant if p < 0.05.

NSCLC cell lines

The human adenocarcinoma alveolar basal epithelial cell line, A549, and the human lung squamous cell carcinoma cell line, SK-MES-1, were obtained from the American Tissue Culture Collection. A549 cells were cultured in F-12 (Ham) medium...
supplemented with 10% FBS, 2 mM L-glutamine, 50 mg/mL streptomycin and 50 U/mL penicillin. SK-MES-1 cells were maintained in Eagle’s minimum essential medium supplemented with 10% FBS, 2 mM L-glutamine, 0.1 M non-essential amino acids, 50 mg/mL streptomycin and 50 U/mL penicillin (Gibco-BRL and Thermo-Scientific). Cells were maintained at 37°C in a humidified atmosphere of 5% CO₂ and split when they reached 80% confluency.

Epigenetic agents

5-aza-2′deoxycytidine (DAC) was obtained from Merck (189825) and used at concentrations ranging from 50 nM to 5 μM for up to 72 hours. Gemcitabine hydrochloride (2′-deoxy-2′, 2′difluorocytidine hydrochloride; GEM) was obtained from Eli Lilly (0002-7501-01, 0002-7502-01) and used at 200 nM to 1 μM for 24 h. Trichostatin A (TSA) was obtained from Calbiochem (647926) and used at 250 ng/ml for 24 h. Suberanilohydroxamic acid (SAHA or Vorinostat) was obtained from Caymen Chemicals (10009929) and used at 5 μM.

Analysis of CD1d mRNA expression

Total RNA was extracted using TRI reagent (Sigma-Aldrich; T9424) according to the manufacturer’s instructions and was quantified using a Nanodrop ND-1000 Spectrophotometer (Labtech). cDNA was generated from 1 μg of total RNA in 1 h reactions at 42°C using RevertAid reverse transcriptase, deoxynucleotides (Thermo Scientific; EPO441 and 10297018) and oligo-dT17-18 primers (Eurofins) according to the manufacturer’s instructions.

Cell lines were examined for the expression of CD1d (234 bp) and β-actin (510 bp) by RT-PCR using the following primers: forward 5′-AAGCCTGTATGGGTGAAG-3′ and reverse 5′-GACTGCCAAGGCAATCAAGC-3′ for CD1d and forward 5′-AGCACCCTGTGTGGGCTACAG-3′ and reverse 5′-TGTTTGAGACCTTCAACACCC-3′ for β-actin obtained from Harvard PrimerBank. Cycling conditions consisted of 95°C for 5 min, followed by 35 repeat cycles of 1 min at 94°C, 1 min at the target gene annealing temperature (56°C for both CD1d and β-actin), and 1 min at 72°C with a final extension at 72°C for 10 min. Experiments conducted on cell lines were carried out in triplicate and PCR products were electrophoresed on 1% agarose gels and quantified using TINA 2.09c (Raytest) densitometry software. Target mRNA expression was standardised against β-actin controls, and expressed as a ratio of target mRNA expression:β-actin expression.

Validation of a subset of RT-PCR results was confirmed using SYBR green based quantitative real-time PCR (RT-qPCR). RT-qPCR reactions were carried out for CD1d using the same primers as above with the following primers for 18S rRNA used as the reference. Forward: 5′-GATGGGCGCGGG-AAAAATAG-3′ and Reverse: 5′-GCGTGGATTCTGCATAA TGTT-3′.

qPCRs were carried out on a PCRmax Eco 48 using SYBR Green qPCR Master Mix (Bimake) and a 2-step qPCR program with the following cycling parameters: An initial polymerase activation of 95°C for 10 minutes followed by 40 cycles of 95°C for 15 seconds and annealing/amplification at 58°C for 60 seconds. A melting curve analysis was conducted at the end of each PCR using 95°C for 15 seconds, 55°C for 15 seconds and a final 95°C for 15 seconds. Data were analysed using the default in-built ΔΔCq analysis settings for relative quantification (Relative Expression) in the Eco Study software.

Chromatin immunoprecipitation (ChiP) assays

Chromatin immunoprecipitation (ChiP) was performed as follows: following treatments, cells were fixed with 1% formaldehyde, suspended in SDS lysis buffer (Merck Millipore; 20–163) and sonicated until DNA was fragmented into lengths of between 200 and 1000 bp. Aliquots of this sheared DNA were subsequently immunoprecipitated using the OneDayChiP Kit (Diagenode; C01010081) according to the manufacturer’s instructions.

The antibodies used for immunoprecipitation were as follows: pan acetylated-histone H3 (H3Ac), pan acetylated-histone H4 (H4Ac), acetylated-histone H3 lysine 9 (H3K9Ac), acetylated-histone H3 lysine 9/14 (H3K9/K14Ac), methylated histone H3 lysine 4 (H3K4Me), di-methylated histone H3 lysine 4 (H3K4Me2), di-methylated histone H3 lysine 9 (H3K9Me2), acetylated histone H3 lysine 9 phosphoserine 10 (H3K9S10), tri-methylated histone H4 lysine 20 (H4K20Me3) and tri-methylated histone H3 lysine 27 (αH3K27Me3). All antibodies were obtained from Milipore and Sigma-Aldrich. A no-antibody control was included to test for specificity.

Primers used to study the promoter region of CD1d by ChiP (211 bp) (Forward 5′-CCACCTAGAGACATGTACTGC-3′, Reverse 5′-CGCTCACCCTCAAGTTCTTCC-3′) were purchased from Sigma Aldrich. PCR cycling condition consisted of: 95°C for 5 min followed by 40 repeat cycles of 95°C for 1 min, 60°C for 1 min, and 72°C for 1 min with a final extension at 72°C for 10 min.

Generation and maintenance of iNKT cell lines

iNKT cells were enriched from total human PBMC by magnetic bead separation using anti-iNKT cell Microbeads (Miltenyi Biotec; 130-094-842) followed by sorting of Vα24Jα18 CD3+ cells using a MoFlo XDP Cell Sorter (Beckman Coulter). Highly purified iNKT cells were expanded by culturing 1,000 iNKT cells in the wells of a 96-well round bottom microtitre plate, in iNKT cell medium (RPMI 1640 containing 0.05 mM L-glutamine, 10% HyClone FBS, 50 mg/mL streptomycin, 50 U/mL penicillin, 2.5 μg/ml amphotericin B – fungizone, 25 mM HEPES, 50 μM 2-mercaptoethanol, 1 mM sodium pyruvate, 1% non-essential amino acids mixture and 1% essential amino acids mixture; Gibco-BRL and Thermo-Scientific) and stimulating them with the iNKT cell glycolipid ligand α-GalCer (100 ng/ml; Funakoshi; KR7000) and 250 U/ml IL-2 (Miltenyi Biotec; 130-097-745) in the presence of an excess (2 x 10⁴) irradiated allogeneic PBMC prepared from two donors. Stock α-GalCer was thawed followed by heating to 80°C for 2 minutes, sonication for 10 minutes and vortexing for 1 minute before diluting to the required concentration in iNKT cell medium followed by heating to 80°C for 2 minutes, sonication for 5 minutes and vortexing for 1 minute before each further dilution. After 24 hours and again after 48 hours and
subsequently every 3–4 days, medium was replaced with fresh iNKT cell medium containing 250 U/ml IL-2. Cells were expanded for a minimum of 3 weeks before being used in experiments. iNKT cells were kept at high cell densities and split 1 in 2 in fresh 96-well plates when multiple cell layers were observed using an inverted microscope. Cells were re-stimulated as above every 4–6 weeks. The purities of iNKT cells were >98% as determined by flow cytometry.

**CD107a degranulation assay**

Cytolytic degranulation by iNKT cells cultured with glycolipid-pulsed NSCLC cells was examined by flow cytometric analysis of CD107a expression by iNKT subsets. A549 or SK-MES-1 cells were treated with PBS or DAC (50 nM, 100 nM and 1 μM) at 24, 48 and 72 hours. Methanol was used as a vehicle control. After a rest period of 3 days the cells were pulsed with either 100 ng/ml α-GalCer or 10 ng/ml 7DW8-5 (Funakoshi) for 24 hours, and then co-cultured with iNKT cells for 4 hours at 1:1 ratios in the presence of anti-CD107a FITC mAb. In some wells, 10 μg/ml of a blocking antibody specific for CD1d (clone CD1d42; BD Biosciences) was included. Monensin (25 μM) was added after 1 hour to prevent proteolysis of the mAb conjugate upon reinternalization of CD107a. iNKT cells treated with 50 ng/ml PMA and 1 μg/ml ionomycin were used as positive controls. Cytolytic degranulation by iNKT cells was examined by flow cytometric analysis of CD107a expression. We previously have shown that CD107a expression by iNKT cells directly correlates with target cell death.11

**Statistical analysis**

Survival analysis of NSCLC patient groups in was carried out using Lung Cancer Explorer and KMPlot analysis.44 Statistical analysis of other data was performed using GraphPad Prism v5.0. Data were expressed as mean ± standard error of the mean and analysed using one- or two-way ANOVA with either Bonferroni or Dunnett’s post-hoc test or a t test with Welch’s correction. The Bonferroni Test was used for multiple comparison analysis while Dunnett’s Post Test was used to compare each sample mean against a control mean. Welch’s correction was used for unequal sample sizes and does not assume that the variances of the two populations are equal. The data was considered significant if \( p < 0.05 \).

**Abbreviations**

| Abbreviation | Definition |
|--------------|------------|
| α-GalCer | α-galactosylceramide |
| BAL | bronchoalveolar lavage |
| DAC | Decitabine (5-Aza-2'-Deoxycytidine) |
| DNMT | DNA methyltransferases |
| DNMTi | DNA methyltransferase inhibitor |
| GEM | gemcitabine hydrochloride |
| HDAC | histone deacetylase |
| iNKT cell | invariant natural killer T cell |
| KMPlot | Kaplan-Meier Plotter |
| NSCLC | non-small cell lung cancer |
| SAHA | suberoylanilide hydroxamic acid |
| TSA | trichostatin A |

**Disclosures of potential conflicts of interest**

No potential conflicts of interest are disclosed.

**Acknowledgments**

This research was funded by a grant from Molecular Medicine Ireland. The authors would like to thank the patients and control subjects who were enrolled in this study; the Irish Blood Transfusion Service for kindly providing buffy coat packs; Conleth Feighery, Mark Little, Andrea Petrasca, Yasmeen Ghniew, Pádraic Dunne, Tanya Coulter, Serena Arduini, Christina Maher and Ashanty Melo Rodriguez for helpful discussions.

**Funding**

This research was funded by a grant from Molecular Medicine Ireland, (Clinical and Translational Research Scholars Programme PhD Project 7F76D).

**Author contributions**

É. Dockry, S.G. Gray and D.G. Doherty designed the experiments. É. Dockry performed the experiments. S. O’Leary, L.E. Gleson, J. Lyons and J. Keane managed the patients and obtained blood and BAL specimens. É. Dockry, S.G. Gray and D.G. Doherty wrote the manuscript.

**ORCID**

Steven G. Gray http://orcid.org/0000-0002-5850-6392
Derek G. Doherty http://orcid.org/0000-0002-4394-658X

**References**

1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:87–108. doi:10.3322/caac.21262. PMID:25651787.
2. Currow DC, You H, Aranda S, McCaughan BC, Morrell S, Baker DF, Walton R, Roder DM. What factors are predictive of surgical resection and survival from localised non-small cell lung cancer? Med J Aust. 2014;201:475–480. doi:10.5694/jma14.00365. PMID:25332036.
3. Pujol JL, Barlesi F, Daurès JP. Should chemotherapy combinations for advanced non-small cell lung cancer be platinum-based? A meta-analysis of phase III randomized trials. Lung Cancer. 2006;51:335–345. doi:10.1016/j.lungcan.2005.11.001. PMID:16478643.
4. Bendelac A, Savage PB, Teyton L. The biology of NKT cells. Annu Rev Immunol. 2007;25:297–336. doi:10.1146/annurev.immunol.25.022106.141711. PMID:17150027.
5. Salio M, Silk JD, Jones EY, Cerundolo V. Biology of CD1- and MR1-restricted T cells. Annu Rev Immunol. 2014;32:323–366. doi:10.1146/annurev-immunol-032713-120243. PMID:24499274.
6. Kawano T, Cui J, Koezuka Y, Toura I, Kaneko Y, Motoki K, Ueno H, Nakagawa R, Sato H, Kondo E, et al. CD1d-restricted and TCR-mediated activation of valpha14 NKT cells by glycosylceramides. Science. 1997;278:1623–1626. doi:10.1126/science.278.5343.1626. PMID:9374463.
7. Cui J, Shin T, Kawano T, Sato H, Kondo E, Toura I, Kaneko Y, Kosaki H, Kanno M, Taniguchi M. Requirement for Vα14 NKT cells in IL-12-mediated rejection of tumors. Science. 1997;278:1623–1626. doi:10.1126/science.278.5343.1623. PMID:9374462.
8. Metelitsa LS, Naidenko OV, Kant A, Wu HW, Loza MJ, Perussia B, Kroenberg M, Seeger RC. Human NKT cells mediate antitumor cytotoxicity directly by recognizing target cell CD1d with bound ligand or indirectly by producing IL-2 to activate NK cells. J Immunol. 2001;167:3114–3122. doi:10.4049/jimmunol.167.6.3114. PMID:11544296.
9. Exley M, Garcia J, Balk SP, Porcelli S. Requirements for CD1d recognition by human invariant Valpha24+ CD4+ CD8- T cells. J Exp Med 1997;186:109–120. doi:10.1084/jem.186.1.109. PMID:9207002.
10. Gumperz JE, Miyake S, Yamamura T, Brenner MB. Functionally distinct subsets of CD1d-restricted natural killer T cells revealed by CD1d tetramer staining. J Exp Med. 2000;195:625–36. doi:10.1084/ jem.20011786. PMID:11877485.

11. O’Reilly V, Zeng SG, Bricard G, Atzberger A, Hogan AE, Jackson J, Feighery C, Porcelli SA, Doherty DG. Distinct and overlapping effector functions of expanded human CD4a+, CD8a+ and CD4a−CD8a− invariant natural killer T cells. PLoS One. 2011;6:e28648. doi:10.1371/journal.pone.0028648. PMID:22174584.

12. Kitamura H, Iwakabe K, Yahata T, Nishimura S, Ohta A, Ohmi Y, Sato M, Takeda K, Okumura K, Van Kaer L, et al. The natural killer T cell (NKT) cell ligand α-galactosylceramide demonstrates its immunopotentiating effect by inducing interleukin (IL)-12 production by dendritic cells and IL-12 receptor expression on NKT cells. J Exp Med. 1999;189:1121–1128. doi:10.1084/jem.189.11.2121. PMID:10190903.

13. Fuji S, Shimizu K, Hemmi H, Steinman RM. Innate Var14+ natural killer T cells mature dendritic cells, leading to strong adaptive immunity. Immunol Rev. 2007;202:183–198. doi:10.1111/j.1600-065X.2007.00561.x. PMID:1799847.

14. Galli G, Nuti S, Tavarnini S, Galli-Stampino S, DellaBonina P, Abbrignani S. CD1d-restricted help to B cells by human invariant natural killer T lymphocytes. J Exp Med. 2003;197:1051–1057. doi:10.1084/jem.20022161. PMID:12695492.

15. Zeng SG, Ghnewa YG, O’Reilly VP, Lyons VG, Atzberger A, Hogan AE, Exley MA, Doherty DG. Human invariant NKT cell subsets differentially promote differentiation, antibody production, and T cell stimulation by B cells in vitro. J Immunol. 2013;191:1666–1676. doi:10.4049/jimmunol.1303029. PMID:24913977.

16. Crowe NY, Coquet JM, Berzins SP, Kyparissoudis K, Keating R, Pellicci DG, Hayakawa Y, Godfrey DJ, Smyth MJ. Differential antitumor immunity mediated by NKT cell subsets in vivo. J Exp Med. 2005;202:1279–1288. doi:10.1084/jem.20050953. PMID:16275765.

17. Macho-Fernandez E, Cruz LJ, Ghinnagow R, Fontaine J, Bialecki E, Blomberg BM, et al. Peripheral blood IFN-γ production by invariant NKT cells in cancer patients is independent of tumor type or tumor load. Int J Cancer. 2005;201:1503–1513. doi:10.1002/ijc.20395. PMID:15305372.

18. Tahir SM, Cheng O, Shaulov A, Koezuka Y, Bubley GJ, Wilson SB, Reilly VP, Lyons VG, Atzberger A, Hogan AE, Exley MA, Doherty DG. Human invariant NKT cell subsets differentially promote differentiation, antibody production, and T cell stimulation by B cells in vitro. J Immunol. 2013;193:961–969. doi:10.4049/jimmunol.1303029. PMID:24913977.

19. Tahir SM, Cheng O, Shaulov A, Koezuka Y, Bubley GJ, Wilson SB, Balk SP, Exley MA. Loss of IFN-γ production by invariant NKT cells in advanced cancer. J Immunol. 2001;167:4046–4050. doi:10.4049/jimmunol.167.7.4046. PMID:11564825.

20. Kenna T, Golden-Mason L, Porcelli SA, Koezuka Y, Hegarty JE, O’Farrelly C, Doherty DG. NKT cells from normal and tumor-bearing human livers are phenotypically and functionally distinct from murine NKT cells. J Immunol. 2003;171:1775–1779. doi:10.4049/jimmunol.171.4.1775. PMID:12902477.

21. Molling JW, Kimmich R, Feighery C, Porcelli SA, Doherty DG. Distinct and overlapping effector functions of expanded human CD4a+, CD8a+ and CD4a−CD8a− invariant natural killer T cells. PLoS One. 2011;6:e28648. doi:10.1371/journal.pone.0028648. PMID:22174584.

22. Kim H, Kwon YM, Kim JS, Han J, Shim YM, Park J, Kim DH. Elevated mRNA levels of DNA methyltransferase-1 as an independent prognostic factor in primary nonsmall cell lung cancer. Cancer. 2006;107:1042–1049. doi:10.1002/cncr.21222. PMID:16888795.

23. Lin RK, Hsu HS, Chang JW, Chen CY, Chen JT, Wang YC. Alteration of DNA methyltransferases contributes to 5′ CpG methylation and poor prognosis in lung cancer. Lung Cancer. 2007;55:205–213. doi:10.1016/j.lungcan.2006.10.022. PMID:17140965.

24. Zhang GL, Yan H, Wang X, Yang J, Miao F, Shen C, Zhang J. Hypermethylation of Dnmt3b is associated with HLA class I down-regulation in lung cancer patients. Lung Cancer. 2010;68:285–290. doi:10.1016/j.lungcan.2010.04.002. PMID:20406540.

25. Brock MV, Hooker CM, Ota-Machida E, Han Y, Guo M, Ames S, Gilkerson S, Plantadosi S, Gabrielson E, Pridham G, et al. DNA methylation markers and early recurrence in stage I lung cancer. N Engl J Med. 2008;358:1118–1128. doi:10.1056/NEJMoa0706550. PMID:18337602.

26. Sterlacci W, Tzankov A, Veits L, Zelger B, Bihl MP, Hoenger A, Augustin F, Fieg M, Savic. S. A comprehensive analysis of p16 expression, gene status, and promoter hypermethylation in surgically resected non-small cell lung carcinomas. J Thorac Oncol. 2011;6:1649–157. doi:10.1097/JTO.0b013e3182295745. PMID:21857254.

27. Selamat SA, Chung BS, Girard L, Zhang W, Zhang Y, Campan M, Siegmond KD, Koss MN, Hagen JA, Lam WL, et al. Genome-scale analysis of DNA methylation in lung adenocarcinoma and integration with mRNA expression. Genome Res. 2012;22:1197–1211. doi:10.1101/ gr.326621.111. PMID:22613842.

28. Kim H, Kwon YM, Kim JS, Han J, Shim YM, Park J, Kim DH. Elevated mRNA levels of DNA methyltransferase-1 as an independent prognostic factor in primary nonsmall cell lung cancer. Cancer. 2006;107:1042–1049. doi:10.1002/cncr.21222. PMID:16888795.

29. Lin RK, Hsu HS, Chang JW, Chen CY, Soo C, Bihl MP, Hoenger A, Augustin F, Fieg M, Savic. S. A comprehensive analysis of p16 expression, gene status, and promoter hypermethylation in surgically resected non-small cell lung carcinomas. J Thorac Oncol. 2011;6:1649–157. doi:10.1097/JTO.0b013e3182295745. PMID:21857254.

30. Selamat SA, Chung BS, Girard L, Zhang W, Zhang Y, Campan M, Siegmond KD, Koss MN, Hagen JA, Lam WL, et al. Genome-scale analysis of DNA methylation in lung adenocarcinoma and integration with mRNA expression. Genome Res. 2012;22:1197–1211. doi:10.1101/ gr.326621.111. PMID:22613842.
B (MICA) by 5-aza-2′-deoxycytidine. Biochem Biophys Res Commun. 2008;360:570–578. doi:10.1016/j.bbrc.2008.03.131. PMID:18395517.

41. Chávez-Blanco A, De la Cruz-Hernández E, Dominguez GI, Rodríguez-Cortez O, Alatorre B, Pérez-Cárdenas E, Chacón-Salinas R, Trejo-Becerril C, Taja-Chayeb L, Trujillo JE, et al. Upregulation of NKG2D ligands and enhanced natural killer cell cytotoxicity by hydralazine and valproate. Int J Oncol. 2011;39:1491–1499. doi:10.3892/ijol.2011.1144. PMID:21805029.

42. Yang PM, Lin PJ, Chen CC. CD1d induction in solid tumor cells by histone deacetylase inhibitors through inhibition of HDAC1/2 and activation of Sp1. Epigenetics. 2012;7:390–399. doi:10.4161/epi.19373.

43. Sharma S, Kelly TK, Jones PA. Epigenetics in cancer. Carcinogenesis. 2010;31:27–36. doi:10.1093/carcin/bgp220. PMID:19752007.

44. Gyorffy B, Suworik P, Budczies J, Lángczyk A. Online survival analysis software to assess the prognostic value of biomarkers using transcriptomic data in non-small-cell lung cancer. PLoS One. 2013;8:e82241. doi:10.1371/journal.pone.0082241. PMID:24367507.

45. Loza MJ, McCall CE, Li L, Isaacs WB, Xu J, Chang BL. Assembly of inflammation-related genes for pathway-focused genetic analysis. PLoS One. 2007;2:e1035. doi:10.1371/journal.pone.0001035. PMID:17940599.

46. Gray SG, Baird AM, O’Kelly F, Nikolaïdis G, Almgren M, Meunier A, Dockery E, Hollywood D, Ekström TJJ, Perry AS, et al. Gemcitabine reactivates epigenetically silenced genes and functions as a DNA methyltransferase inhibitor. Int J Mol Med. 2012;30:1505–11. doi:10.3892/ijmm.2012.1138. PMID:23007409.

47. Nguyen CT, Weisenberger DJ, Velicescu M, Gonzales FA, Lin JC, Liang G, Jones PA. Histone H3 lysine 9 methylation is associated with aberrant gene silencing in cancer cells and is rapidly reversed by 5-aza-2′-deoxycytidine. Cancer Res. 2002;62:6456–6461. doi:10.1158/0008-5472.CAN-02-1436. PMID:12473579.

48. Abele R, Clavel M, Dodion P, Bruniush C, Gundersen S, Smyth J, Renard J, van Glabbeke M, Pinedo HM. The EORTC Early Clinical Trials Cooperative Group experience with 5-aza-2′-deoxycytidine. Eur J Cancer 1987;23:1921–1924. doi:10.1016/0755-5779(87)90060-5. PMID:2449354.

49. Tsai HC, Li H, Van Neste L, Cai Y, Robert C, Rassoul FV, Shin JJ, Harbom KM, Beatty R, Pappou E, et al. Transient low doses of DNA-demethylating agents exert durable antitumor effects on hematological and epithelial tumor cells. Cancer Cell. 2012;21:430–46. doi:10.1016/j.ccr.2011.12.029. PMID:22439938.

50. Giaccone G, Punt CJ, Ando Y, Ruitter R, Nishi N, Peters M, von Blomberg BM, Scheper RJ, van der Vliet HJ, van den Eertwegh AJ, et al. Phase I study of the natural killer T-cell ligand α-galactosylceramide (KRN7000) in patients with solid tumors. Clin Cancer Res. 2002;8:3702–3709. PMID:12473579.

51. Ishikawa A, Motohahi S, Ishikawa E, Fuchida H, Higashino K, Otsuji M, Izasa T, Nakayama T, Taniguchi M, Fujisawa T. A phase I study of α-galactosylceramide (KRN7000)-pulsed dendritic cells in patients with advanced and recurrent non-small cell lung cancer. Clin Cancer Res. 2005;11:1910–1917. doi:10.1158/1078-0432.CCR-04-1453. PMID:15756017.

52. Metelitsa LS, Weinberg KI, Emanuel PD, Seeger RC. Expression of CD1d by myelomonocytic leukemias provides a target for cytotoxic NKT cells. Leukemia. 2003;17:1068–1077. doi:10.1038/sj.leu.2402943. PMID:12764370.

53. Jäger D, Jäger E, Knuth A. Immune responses to tumour antigens: implications for antigen specific immunotherapy of cancer. J Clin Pathol. 2001;54:669–674. doi:10.1111/j.1365-2141.1999.00027.x. PMID:11533070.

54. Algarra I, García-Lora A, Cabrera T, Ruiz-Cabello F, Garrido F. The selection of tumor variants with altered expression of classical and nonclassical MHC class I molecules: implications for tumor immune escape. Cancer Immunol Immunother. 2004;53:904–910. doi:10.1007/s00262-004-0517-9. PMID:15069855.

55. Hix LM, Shi YH, Brutkiewicz RR, Stein PL, Wang CR, Zhang M. CD1d-expressing breast cancer cells modulate NKT cell-mediated antitumor immunity in a murine model of breast cancer metastasis. PLoS One. 2011;6:e20702. doi:10.1371/journal.pone.0020702. PMID:21695190.

56. Miura S, Kawana K, Schust DJ, Fujii T, Yokoyama T, Iwasawa Y, Nagamatsu T, Adachi K, Tomio A, Tomio K, et al. CD1d, a sentinel molecule bridging innate and adaptive immunity, is downregulated by the human papillomavirus (HPV) E5 protein: a possible mechanism for immune evasion by HPV. J Virol. 2010;84:11641–23. doi:10.1128/JVI.01053-10. PMID:20810727.

57. Probst AV, Dunleavy E, Almouzni G. Epigenetic inheritance during the cell cycle. Nat Rev Mol Cell Biol. 2009;10:192–206. doi:10.1038/nrm2640. PMID:19234478.

58. Cortez CC, Jones PA. Chromatin, cancer and drug therapies. Mutat Res. 2008;647:44–51. doi:10.1016/j.mrfmmm.2008.07.006. PMID:18691602.

59. Bartling B, Hofmann HS, Boettger T, Hansen G, Burdach S, Silber RE, Simm A. Comparative application of antibody and gene array for expression profiling in human squamous cell lung carcinoma. Lung Cancer. 2005;49:145–154. doi:10.1016/j.lungcan.2005.02.006. PMID:16022908.

60. O’Leary SM, Coleman MM, Chew WM, Morrow C, Maughlin AM, Gleeson LE, O’Sullivan MP, Keane J. Cigarette smoking impairs human pulmonary immunity to Mycobacterium tuberculosis. Am J Respir Crit Care Med. 2014;190:1430–1436. doi:10.1164/rccm.201407-1385OC. PMID:25390734.

61. Cancer Genome Atlas Research Network. Comprehensive molecular characterization of squamous cell lung cancers. Nature. 2014;511:453–500. doi:10.1038/nature13385. PMID:25079552.

62. Cancer Genome Atlas Research Network. Comprehensive genomic characterization of squamous cell lung cancers. Nature. 2012;489:519–525. doi:10.1038/nature11404. PMID:22960745.

63. Wang X, Spandidos A, Wang H, Seed B. PrimerBank: a PCR primer database for quantitative gene expression analysis, 2012 update. Nucleic Acids Res. 2012;40:D1144–9. doi:10.1093/nar/gkr1013. PMID:22086960.

64. Chen QY, Zhang T, Pincus SH, Wu S, Ricks D, Liu D, Sun Z, Maclaren N, Lan MS. Human CD1D gene expression is regulated by LIF through distal promoter regulatory elements. J Immunol. 2010;184:5047–5054. doi:10.4049/jimmunol.0901912. PMID:20363964.